Luspatercept/Lenalidomide Combo Demonstrates Safety and Early Efficacy in Lower-Risk, Non-Del(5q) MDS
WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL
Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups